Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Paying users area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Bristol-Myers Squibb Co., common-size consolidated balance sheet: liabilities and stockholders’ equity
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Balance sheet item | Description | The company |
---|---|---|
Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | Bristol-Myers Squibb Co. current liabilities as a percentage of total liabilities and equity increased from 2021 to 2022 and from 2022 to 2023. |
Non-current liabilities | Amount of obligation due after one year or beyond the normal operating cycle, if longer. | Bristol-Myers Squibb Co. non-current liabilities as a percentage of total liabilities and equity decreased from 2021 to 2022 but then slightly increased from 2022 to 2023. |
Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | Bristol-Myers Squibb Co. total liabilities as a percentage of total liabilities and equity increased from 2021 to 2022 and from 2022 to 2023. |
Total BMS shareholders’ equity | Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | Bristol-Myers Squibb Co. total BMS shareholders’ equity as a percentage of total liabilities and equity decreased from 2021 to 2022 and from 2022 to 2023. |